Review your GLP-1 provider's public record before you enroll
Before you start a GLP-1, check three things: the program's FDA warning-letter record, the pharmacy that makes your medicine, and the side effects of your exact drug and dose.
Our warning tracker documents 16 sourced FDA letters dated across 2025 and 2026. It is a curated subset, not a count of every agency action.
No provider pays to appear in these resources.
Check a program before you pay
Warning letters, the pharmacy behind your medicine and court cases.
Check dated complaint and rating records alongside these checks. Individual reports do not establish clinical quality or a failure rate.
- FDA warning letters and alertsReview 16 sourced FDA warning-letter records involving compounded GLP-1 marketing or sales. This curated tracker links every row to fda.gov and is not exhaustive.16sourced warning records
- Is compounded semaglutide safe?Run six checks on a compounded GLP-1 provider before you pay: the named pharmacy, its accreditation, a Certificate of Analysis and a US-licensed prescriber.6checks before you pay
- Check a program's public recordReview warning-letter, pharmacy-disclosure, licensing-status, and public-record fields for 39 tracked records. Unknown fields stay Unknown; the tool does not certify safety or compliance.39public records tracked
- GLP-1 lawsuit trackerRead dated court records and distinguish allegations, procedural updates and outcomes.Court recordsdated lawsuit context
Side effects by medicine
The percentages come from separate trials with different doses and populations. They are not a head-to-head safety ranking or a prediction of your symptoms. Open each guide for the table and prescribing-information source.
- Side effects across all GLP-1sRead side-effect rates with the medication, dose and study population identified. Find warning signs and symptom-management resources. Separate trials cannot tell you which drug you will tolerate best.By dosetrial-specific rates
- Wegovy side effectsCheck reported side effects for Wegovy injection, warning symptoms and questions to ask before a dose change. Read the dose and study context alongside each percentage.44%nausea, adult 2.4 mg injection trials
- Zepbound side effectsCheck Zepbound side-effect rates by assigned dose, warning symptoms, hair-loss evidence and questions for your prescriber. Trial rates do not predict symptoms at each step of treatment.25–29%nausea, adult 5–15 mg trials
- Ozempic side effectsRead Ozempic injection side-effect rates from diabetes trials, eye-related warnings and low-blood-sugar precautions with insulin or sulfonylureas. Prepare questions for your prescriber.20.3%nausea, adult 1 mg diabetes trials
- Foundayo side effectsRead Foundayo side-effect rates with dose and placebo context, warning symptoms and a checklist for discussing symptoms and other medicines with your prescriber.35%nausea, adult 17.2 mg trials
- Mounjaro side effectsRead Mounjaro side-effect rates from diabetes trials, warning symptoms and precautions when using insulin or sulfonylureas. Dose changes should follow your prescriber's instructions.18%nausea, adult 15 mg diabetes trials
- Rybelsus side effectsRead Rybelsus 7 mg and 14 mg side-effect rates from diabetes trials, warning symptoms and the labeled tablet-taking instructions. These rates do not describe oral Wegovy.20%nausea, adult 14 mg diabetes trials
Three things to do before you start
Check the program
Use our Warning & Transparency Checker to review sourced FDA letters and claim-level pharmacy details. "Unknown" means we found nothing either way.
Confirm the current pharmacy and prescriber with the program before you enroll.
Start low, go slow
Follow the dose schedule you are prescribed. Moving up too fast makes stomach side effects worse. Use our dosing timeline tool.
What the doctors say about GLP-1 safety
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“Americans should be confident that the prescription drugs they take are safe. By strengthening oversight of imported APIs and cracking down on illegal drugs entering the U.S., we are taking aggressive action to protect consumers from poor-quality or dangerous GLP-1 drugs.”
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.